Enliven Cash And Short Term Investments from 2010 to 2024
| ELVN Stock | 24.54 0.87 3.42% |
Cash And Short Term Investments | First Reported 2019-12-31 | Previous Quarter 312.4 M | Current Value 291.8 M | Quarterly Volatility 102.2 M |
Check Enliven Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enliven Therapeutics' main balance sheet or income statement drivers, such as Other Operating Expenses of 87.7 M, Research Development of 67.8 M or Total Operating Expenses of 87.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.1. Enliven financial statements analysis is a perfect complement when working with Enliven Therapeutics Valuation or Volatility modules.
Enliven | Cash And Short Term Investments |
Latest Enliven Therapeutics' Cash And Short Term Investments Growth Pattern
Below is the plot of the Cash And Short Term Investments of Enliven Therapeutics over the last few years. Short Term Investments is an account in the current assets section of Enliven Therapeutics balance sheet. This account contains Enliven Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Enliven Therapeutics fairly quickly. It is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. Enliven Therapeutics' Cash And Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enliven Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Cash And Short Term Investments | 10 Years Trend |
|
Cash And Short Term Investments |
| Timeline |
Enliven Cash And Short Term Investments Regression Statistics
| Arithmetic Mean | 63,235,693 | |
| Geometric Mean | 25,412,414 | |
| Coefficient Of Variation | 140.94 | |
| Mean Deviation | 69,159,991 | |
| Median | 9,671,000 | |
| Standard Deviation | 89,122,493 | |
| Sample Variance | 7942.8T | |
| Range | 258.4M | |
| R-Value | 0.79 | |
| Mean Square Error | 3276.6T | |
| R-Squared | 0.62 | |
| Significance | 0.0005 | |
| Slope | 15,652,874 | |
| Total Sum of Squares | 111199.5T |
Enliven Cash And Short Term Investments History
About Enliven Therapeutics Financial Statements
Enliven Therapeutics investors utilize fundamental indicators, such as Cash And Short Term Investments, to predict how Enliven Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash And Short Term Investments | 253.1 M | 265.8 M |
Pair Trading with Enliven Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enliven Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enliven Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Enliven Stock
| 0.84 | VCNX | Vaccinex | PairCorr |
| 0.72 | GMAB | Genmab AS | PairCorr |
| 0.65 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.61 | LEGN | Legend Biotech Corp | PairCorr |
| 0.59 | KRYS | Krystal Biotech | PairCorr |
The ability to find closely correlated positions to Enliven Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enliven Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enliven Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enliven Therapeutics to buy it.
The correlation of Enliven Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enliven Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enliven Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enliven Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Enliven Therapeutics Correlation against competitors. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.